Shukra Pharmaceuticals Limited
Name and Symbol Change
Shukra Pharmaceuticals Limited will change its name to Shukra Medtech Limited and symbol from SHUKRAPHAR to SHUKRAMED, effective November 20, 2026.
29
total announcements
SHUKRAPHAR.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 19 Nov 2026
Market Cap
₹3,638 Cr
P/E (TTM)
81.4
EPS (TTM)
₹1.01
52W Low
₹40.06
52W High
₹84.80
Dividend Yield
0.01%
Beta
0.55
Price / Book
30.4
Return on Equity
48.08%
Debt / Equity
19.0
Revenue (TTM)
₹111 Cr
Gross Margin
75.31%
Operating Margin
57.88%
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited will change its name to Shukra Medtech Limited and symbol from SHUKRAPHAR to SHUKRAMED, effective November 20, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange that the name has been changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited, with the new name and symbol to be effective from November 20, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 06, 2026, titled "Newspaper Publication of Quarterly Results".
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has reported a significant increase in revenue and net profit for the quarter and six months ended 30 September 2026. The company's revenue from operations stood at ₹44.20 crore, compared with ₹5.88 crore in the same period last year, with a 652% year-over-year growth. The net profit rose to ₹16.01 crore from ₹2.38 crore, with a 573% year-over-year growth. The company's management has attributed the growth to its expansion into the overseas market, particularly in the MedTech segment.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, confirming no deviation or variation in the utilization of proceeds from the object mentioned in the notice of Extra Ordinary general meeting for issuance of convertible warrants on a preferential basis.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted its unaudited financial results for the quarter and half year ended September 30, 2026, showing a net profit of ₹1,601.20 lakhs.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted a revised Chartered Accountant Certificate dated September 16, 2026, in connection with the final application for the change of name from 'SHUKRA PHARMACEUTICALS LIMITED' to 'SHUKRA MEDTECH LIMITED' and the consequent change in symbol.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted its Structured Digital Database (SDD) Compliance Certificate for the quarter ended September 30, 2026, confirming that the company has a SDD in place, with controls in place to access the database, and that all unpublished price sensitive information (UPSI) has been captured in the database.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the change of name from 'SHUKRA PHARMACEUTICALS LIMITED' to 'SHUKRA MEDTECH LIMITED' as approved by the Ministry of Corporate Affairs (MCA).
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of shares on stock exchanges.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 06, 2026, where the Board of Directors approved the allotment of 17,35,000 fully paid-up equity shares to promoters upon conversion of warrants into equity shares.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, clarifying that there is no unannounced material information or pending price-sensitive announcement that could influence the trading volume or price behavior of the Company's shares, attributing the recent spurt in the share price to market driven conditions and natural trading dynamics.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited's stock has experienced significant price movement, prompting the NSE to contact the company for clarification, awaiting response.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. The company has informed the Exchange regarding voting results of the resolutions passed in the meeting.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026. The 33rd Annual General Meeting (AGM) of the Company was held through video conferencing, in compliance with the applicable provisions of the Companies Act, 2013, and SEBI circulars.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has announced the record date for determining the eligibility of members to receive the final dividend for the financial year ended 31 March 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026, to consider and adopt audited financial statements for the financial year ended March 31, 2026, approve and declare final dividend, re-appoint a director, and regularize the appointment of an additional independent director.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has rescheduled its 33rd Annual General Meeting (AGM) to September 28, 2026, due to unavoidable administrative exigencies. The revised book closure dates are September 22-28, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the Record Date for determining eligibility for Final Dividend for the financial year ended 31 March, 2026.